(Q38126361)

29 August 2017

title

Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents (English)

1 reference

29 August 2017

1 reference

1 reference

Sameer Doshi

1

1 reference

29 August 2017

Wojciech Krzyzanski

2

1 reference

29 August 2017

Susan Yue

3

1 reference

29 August 2017

Steven Elliott

4

1 reference

29 August 2017

Andrew Chow

5

1 reference

29 August 2017

Juan José Pérez-Ruixo

6

1 reference

29 August 2017

publication date

1 December 2013

1 reference

Clinical Pharmacokinetics

29 August 2017

published in

1 reference

29 August 2017

volume

52

1 reference

29 August 2017

issue

12

1 reference

29 August 2017

page(s)

1063-1083

1 reference

Role of the kidney in erythropoiesis

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Cloning and expression of the human erythropoietin gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Isolation and characterization of genomic and cDNA clones of human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Erythropoietins: a common mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Use of recombinant human erythropoietin as an antianemic and performance enhancing drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Development and characterization of novel erythropoiesis stimulating protein (NESP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Enhancement of therapeutic protein in vivo activities through glycoengineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Purification and characterization of hypoxia-inducible factor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Efficiency of signalling through cytokine receptors depends critically on receptor orientation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Expression cloning of the murine erythropoietin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Erythropoietin receptor. Subunit structure and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

A sequential dimerization mechanism for erythropoietin receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Landmark advances in the development of erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Absence of functional EpoR expression in human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Erythropoietin production by interstitial cells of hypoxic monkey kidneys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Circadian rhythm of glomerular filtration rate in normal individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

The HIF Pathway and Erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pharmacokinetics and pharmacodynamics of pegfilgrastim

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Lymphatic transport of proteins after subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Non-linear mixed effect modeling of the time-variant disposition of erythropoietin in anemic cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Population pharmacokinetics of darbepoetin alfa in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Exposure‐Response Modeling of Darbepoetin Alfa in Anemic Patients With Chronic Kidney Disease Not Receiving Dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Clinical pharmacokinetics of epoetin (recombinant human erythropoietin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Change in erythropoietin pharmacokinetics following hematopoietic transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Control of rHuEPO biological activity: the role of carbohydrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Effect of pegylation on pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pegylation: engineering improved biopharmaceuticals for oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

General pharmacokinetic model for drugs exhibiting target-mediated drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Red blood cell survival in long-term dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Kinetics of haematopoietic recovery after dose-intensive chemo/radiotherapy in mice: optimized erythroid support with darbepoetin alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Purification of human erythroid colony-forming units and demonstration of specific binding of erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Neocytolysis: physiological down-regulator of red-cell mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Iron balance in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Treatment of the anemia of chronic renal failure with recombinant human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Identification of Spermine as an Inhibitor of Erythropoiesis in Patients with Chronic Renal Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Do polyamines play a role in the pathogenesis of the anemia of end-stage renal disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Effect of parathyroid hormone on erythropoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Use of breath carbon monoxide measurements to assess erythrocyte survival in subjects with chronic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Biological basis of anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Diversity of mechanism-based pharmacodynamic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Optimizing the use of erythropoietic agents-- pharmacokinetic and pharmacodynamic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Oxygen sensing by HIF hydroxylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0098-X

Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats

21 January 2018

1 reference

12 December 2020

Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration. Preliminary results

1 reference

12 December 2020

ERYTHROCYTOSIS AND HYPERNEPHROMA

1 reference

12 December 2020

Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis

1 reference

12 December 2020

In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep.

1 reference

12 December 2020

Secondary erythrocytosis due to a cerebellar hemangioblastoma: demonstration of erythropoietin mRNA in the tumor

1 reference

12 December 2020

Purification of human erythropoietin

1 reference

12 December 2020

Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta

1 reference

12 December 2020

Lineage-restricted recruitment of immature hematopoietic progenitor cells in response to Epo after normal hematopoietic cell transfection with EpoR

1 reference

12 December 2020

Mapping of the active site of recombinant human erythropoietin

1 reference

12 December 2020

Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells

1 reference

12 December 2020

The in vivo metabolism of recombinant human erythropoietin in the rat.

1 reference

12 December 2020

Characterization and biological effects of recombinant human erythropoietin

1 reference

12 December 2020

The metabolism of recombinant erythropoietin in the isolated perfused rat liver.

1 reference

12 December 2020

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

1 reference

12 December 2020

Serum erythropoietin during autologous bone marrow transplantation: relationship to measures of erythroid activity

1 reference

12 December 2020

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

1 reference

12 December 2020

Physicochemical and biological comparison of recombinant human erythropoietin with human urinary erythropoietin

1 reference

12 December 2020

Erythropoietin: physiology and pharmacology update

1 reference

12 December 2020

Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers

1 reference

12 December 2020

Erythropoietin: structure, control of production, and function

1 reference

12 December 2020

Hemoglobin loss from erythrocytes in vivo results from spleen-facilitated vesiculation

1 reference

12 December 2020

Studies on the production of erythropoietin by isolated perfused organs

1 reference

12 December 2020

Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration

1 reference

12 December 2020

Erythropoietin in aplastic anemia

1 reference

12 December 2020

Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure

1 reference

12 December 2020

Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia

1 reference

12 December 2020

Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration

1 reference

12 December 2020

Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway

1 reference

12 December 2020

Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells.

1 reference

12 December 2020

Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice

1 reference

12 December 2020

Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin

1 reference

12 December 2020

Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis

1 reference

12 December 2020

Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial

1 reference

12 December 2020

Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia

1 reference

12 December 2020

Population pharmacokinetic analysis of pegylated human erythropoietin in rats

1 reference

12 December 2020

Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling.

1 reference

12 December 2020

The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients

1 reference

12 December 2020

Pharmacokinetics tricks and traps: flip-flop models

1 reference

12 December 2020

Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers

1 reference

12 December 2020

Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line, HEL

1 reference

12 December 2020

Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients

1 reference

12 December 2020

The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites

1 reference

12 December 2020

Leiomyoma and erythrocytosis: a tumor producing a factor which increases erythropoietin production. Report of case

1 reference

12 December 2020

Isotope investigations of red cell production and destruction in chronic renal disease

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease

1 reference

12 December 2020

Receptors for erythropoietin in mouse and human erythroid cells and placenta

1 reference

12 December 2020

Operational models of pharmacological agonism.

1 reference

12 December 2020

Physiological and pharmacodynamic considerations for route of EPO administration.

1 reference

12 December 2020

Serum erythropoietin levels in ovarian cancer patients receiving chemotherapy

1 reference

12 December 2020

Circadian rhythm of serum erythropoietin in myelodysplastic syndromes.

1 reference

12 December 2020

Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved.

1 reference

12 December 2020

Enhanced erythropoietin secretion in hepatoblastoma cells in response to hypoxia

1 reference

12 December 2020

The biology and clinical applications of recombinant erythropoietin.

1 reference

12 December 2020

The kidney and erythropoiesis

1 reference

12 December 2020

Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects.

1 reference

12 December 2020

Erythropoietin production in renal tumors

1 reference

12 December 2020

Pharmacokinetics of recombinant human erythropoietin after SC administration and in long-term IV treatment in patients on maintenance hemodialysis

1 reference

12 December 2020

Erythropoietin excretion in bone marrow failure and hemolytic anemia

1 reference

12 December 2020

Pharmacokinetics and distribution of recombinant erythropoietin in rats

1 reference

12 December 2020

Decreased erythropoietin response in patients with the anemia of cancer

1 reference

12 December 2020

The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers

1 reference

12 December 2020

Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production

1 reference

12 December 2020

Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients

1 reference

12 December 2020

Erythropoietin receptor characteristics on primary human erythroid cells

1 reference

12 December 2020

Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis

1 reference

12 December 2020

Erythropoietin production in patients with chronic renal failure

1 reference

12 December 2020

Erythropietic colonies in cultures of human marrow

1 reference

12 December 2020

A pharmacodynamic model of erythropoietin therapy for uremic anemia

1 reference

12 December 2020

Circadian rhythm of erythropoietin in human serum

1 reference

12 December 2020

Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats

1 reference

12 December 2020

The production of an erythropoietic factor by the in situ perfused kidney

1 reference

12 December 2020

Characterization of the anemia associated with chronic renal insufficiency

1 reference

12 December 2020

Sequestration and possible maturation of reticulocytes in the normal spleen

1 reference

12 December 2020

Dynamics of erythropoietin receptor expression on erythropoietin-responsive murine cell lines

1 reference

12 December 2020

The structure of lymphatic capillaries in lymph formation

1 reference

12 December 2020

The effect of erythropoietin on normal and neoplastic cells

1 reference

12 December 2020

CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.

1 reference

12 December 2020

Heat-induced aggregation of recombinant erythropoietin in the intact and deglycosylated states as monitored by gel permeation chromatography combined with a low-angle laser light scattering technique

1 reference

12 December 2020

Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis

1 reference

12 December 2020

In vitro production of erythropoietin by kidneys perfused with a serum-free solution

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys

1 reference

12 December 2020

Anti-Epo receptor antibodies do not predict Epo receptor expression

1 reference

12 December 2020

Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients

1 reference

12 December 2020

Production, utilization and excretion of erythropoietin. I. Chronic anemias. II. Aplastic crisis. 3. Erythropoietic effects of normal plasma

1 reference

12 December 2020

Both proteasomes and lysosomes degrade the activated erythropoietin receptor

1 reference

12 December 2020

10.1007/S40262-013-0098-X

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1042101356

0 references

1 reference